Grail

GRAIL is a health technology company focused on early cancer detection. The company develops blood-based screening approaches for multi-cancer early detection (MCED) with the aim of altering the course of cancer mortality. To this end, it leverages next-generation sequencing large-scale clinical studies and the integration of computer science and data science.

GRAIL’s activities are based on detecting cancer signals by deciphering methylation signatures of cell-free DNA in the bloodstream before symptoms appear across many lethal cancer types. The company’s flagship product is the Galleri® test. The target population for the test is adults with elevated cancer risk, and it is intended to be used alongside standard screening methods. The company is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina and the United Kingdom.

GRAIL’s origins stem from an unexpected discovery in 2015, when non-invasive prenatal tests detected cancer-derived DNA signals in maternal blood that were unrelated to the fetus. In 2016, GRAIL separated as an independent entity to focus on researching this finding. Between 2018 and 2019, it shifted from single-cancer screening to multi-cancer screening, contributing to the development of the MCED category. Between 2020 and 2021, it expanded its clinical capabilities, partnered with the United Kingdom’s National Health Service, and launched the Galleri test commercially. In 2022–2023, the PATHFINDER results were announced, enrollment of 140,000 participants in the NHS-Galleri trial was completed, and public-private partnerships were expanded. In 2024, the company began trading on Nasdaq under the ticker symbol “GRAL” as an independent publicly listed company, deepening its clinical programs and broadening access.

GRAIL’s platform is based on targeted sequencing of methylation patterns in cell-free DNA isolated from peripheral blood, followed by analysis using machine learning classifiers. The biological foundation rests on two principles: the presence of DNA fragments shed by tumors into the bloodstream and distinct methylation patterns unique to different tissue and tumor types. In the analytical workflow, sequencing reads methylation, followed by cancer signal classification and prediction of the likely Cancer Signal Origin (CSO) in a sequential process.

Galleri is a prescription blood test designed to screen for a common cancer signal across more than 50 cancer types during the pre-symptomatic phase. Studies have reported a low false-positive rate, a high probability of cancer presence upon a positive result, and high accuracy in CSO prediction. The test does not assess future genetic risk; any detected signal must be confirmed through established diagnostic methods such as imaging. Galleri is designed for use alongside standard screening in clinical practice.

The company conducts a clinical program encompassing more than 300,000 participants across multicenter prospective designs. The PATHFINDER and PATHFINDER 2 studies examined integration of the test into clinical workflows; the CCGA study provided discovery and validation of the methylation-based approach. The NHS-Galleri trial was designed to evaluate performance and clinical benefit within the UK’s national screening context. SUMMIT, STRIVE, REFLECTION and REACH/Galleri-Medicare studies investigate efficacy, safety, repeat screening and real-world impact across diverse populations. Collectively, the program aims to assess validity and feasibility at a population scale.

GRAIL has established collaborations with pharmaceutical companies, insurers, healthcare systems and public institutions. These include partnerships with AstraZeneca for co-diagnosis and biomarker applications in early-stage cancer and evaluation programs under the U.S. Department of Veterans Affairs ecosystem. In 2023, the company announced a targeted methylation platform for research use, generating evidence for precision medicine applications such as risk stratification, disease classification, tumor burden estimation and longitudinal monitoring.

GRAIL’s CAP-accredited and CLIA-certified laboratory facility exceeds 170,000 square feet. This capacity is planned to support long-term growth. Commercial test availability has expanded incrementally since 2021.

Gregory Summe serves as Chairman of GRAIL’s board of directors, with defined roles for audit, compensation and nominating/governance committees. The executive team includes CEO and board member Bob Ragusa, along with senior leaders responsible for clinical development, software and security, R&D, finance, international business and biopharma, public policy, quality and regulatory affairs. The company receives support from global investors and organizations in pharmaceuticals, technology and healthcare services.

GRAIL’s clinical laboratory is authorized for high-complexity testing under CLIA and accredited by CAP. The performance characteristics of the Galleri test are established by the company; the test has not been approved or cleared by the U.S. Food and Drug Administration. Test results must be interpreted by a healthcare professional in conjunction with the patient’s clinical history and findings; a “Cancer Signal Not Detected” result does not rule out cancer, and a “Cancer Signal Detected” result requires diagnostic confirmation. False-positive and false-negative results may occur.

The company has been recognized in Time’s “Best Inventions” list in 2022, featured in Fast Company’s “World Changing Ideas” and received an Edison Award in 2023. In 2025, it was named to industry-specific “Best Place to Work” lists.

In 2024, expanded access, the announcement of results from two major registration-grade studies and transition to an independent public company were key milestones. Post-2024, the company aims to develop solutions spanning the entire cancer care continuum—not only screening and early detection but also risk stratification, biomarker subtyping, treatment monitoring and recurrence surveillance. According to company statements, hundreds of thousands of Galleri tests have been completed since its market launch, enrollment has been initiated in studies such as REACH, and steps have been taken to increase representation in the Medicare population.

The headquarters is in Menlo Park, California. Operational sites are located in Washington, D.C., Research Triangle Park in North Carolina and the United Kingdom. Corporate information, research opportunities and press releases are published through the company’s official channels.